Zacks Research Upgrades AgomAb Therapeutics (NASDAQ:AGMB) to “Hold”

AgomAb Therapeutics (NASDAQ:AGMB) was upgraded by equities researchers at Zacks Research to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Several other research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. JPMorgan Chase & Co. assumed coverage on AgomAb Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $32.00 target price for the company. Morgan Stanley assumed coverage on AgomAb Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $28.00 price target for the company. Finally, Leerink Partners started coverage on AgomAb Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.00.

AgomAb Therapeutics Stock Performance

AgomAb Therapeutics stock traded down $0.86 during trading hours on Wednesday, reaching $13.35. 37,321 shares of the stock were exchanged, compared to its average volume of 167,831. AgomAb Therapeutics has a 52-week low of $12.66 and a 52-week high of $17.45.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.